Nineteen patients out of 250 subjects with antiphospholipid antibodies, who had initially presented to the lupus clinic at St Thomas's Hospital, London five or more years ago with a history of venous/arterial occlusions, were entered into the study. The patients were divided into two main groups: I those who remained well without any further thromboembolic complications (n= 10); H those who developed recurrent thrombotic events in the five year period (n=9).
tive in all patients, the levels remaining fairly constant. Levels fell in only one patient in group I and in two in group H. Patients in group II had more systemic lupus erythematosus related disease than those in group I; most were receiving concomitant steroid and immunosuppressive therapy, but this did not seem to protect against the development of further occlusions. All patients were given anticoagulation treatment (warfarin/heparin) or salicylates (low dose aspinn 75 mg daily), or both. Patients with deep vein thromboses developed more complications during anticoagulation therapy than those with cerebrovascular symptoms. Problems in anticoagulation control and recurrent thromboses consequent on warfarin withdrawal despite the administra'tion of subcutaneous heparin were responsible for complications in most patients in group H.
Antiphospholipid antibodies-those antibodies responsible for the in vitro lupus anticoagulant test-as well as antibodies directed against negatively charged phospholipids, of which cardiolipin is one example, are associated with a wide variety of clinical complications as a consequence of thrombosis of veins as well as arteries 2: recurrent fetal loss,3 haematological (thrombocytopenia, Coombs' positivity/haemolytic anaemia), dermatological (livedo reticularis, skin nodules/necrosis), and neurological (chorea, transverse myelitis, dementia) complications. 4 These complications in about 50%/o of patients occur in association with systemic lupus erythematosus (SLE) or 'lupuslike' disease, a variant of SLE, with patients essentially showing less than four of the revised criteria for the classification of SLE as laid down by the American Rheumatism Association in 1982. 5 Criteria for an 'antiphospholipid syndrome' were proposed in 1987 by Harris et al, 6 comprising essentially the combination of vascular occlusions and thrombocytopenia accompanied by persisting increases of anticardiolipin antibodies or presence of the lupus anticoagulant, or both. The antiphospholipid syndrome in 50% of patients is seen without any clinical or serological evidence of SLE-the recently defined 'primary' antiphospholipid syndrome. [7] [8] [9] It is still unclear whether these antibodies alone are the direct cause of thrombotic events by a number of differing mechanisms, or whether they constitute 'markers' present in most patients with clotting problems and lupustype illness.
This study aimed at determining whether there was any quantitative change in antibody levels preceding the recurring thrombotic events in patients originally presenting with an antiphospholipid syndrome and what, if any, other 'trigger' factors might contribute to the occurrence of such events in these susceptible patients over a five year period.
Patients and methods All patients were defined as having an 'antiphospholipid syndrome' according to the criteria proposed in 1987.6 Patients with recurrent fetal losses were excluded as they will form part of a separate study. All patients were thrombocytopenic either initially or at some point during the five years. Fluctuations in platelet counts were not considered in the study. Anticardiolipin antibody estimations were performed at three to six monthly intervals at routine follow up visits. The anticardiolipin antibody levels were defined as low (for IgG and IgM anticardiolipin antibody) (<20 units); moderate (20- [12] [13] [14] [15] [16] [17] [18] The levels of anticardiolipin antibody in both groups were almost identical, with similar numbers of patients being in the high, medium, and low positive IgG anticardiolipin antibody range. IgM anticardiolipin antibodies were only present in two patients in group I and two in group II.
Anticardiolipin antibody levels changed in only three patients over the five year period, and in these, levels actually fell. There did not seem to be any sudden rise of anticardiolipin antibody levels in the three to six weeks before the recurrent thrombotic events. It is therefore concluded that the actual levels ofanticardiolipin antibody as monitored in the low, medium, and high ranges did not influence the development of complications in these patients.
Six patients in group I and six in group II were receiving prednisolone treatment. Only one patient was receiving azathioprine in group I, whereas four in group II were receiving it. Pulse cyclophosphamide had been given to two patients in group II but not to any in group I. Background azathioprine treatment did not seem to prevent recurrent complications, nor did the long term administration ofprednisolone. Because only two patients had received pulse cyclophosphamide treatment (for acute renal disease in both) no assessment of the efficacy of this form of treatment in the prevention of thrombotic complications is possible. The use of dipyridamole seemed to be ineffective alone in the prevention of thrombosis. Salicylates (low dose aspirin 75 mg daily) were effective in the prevention of further thrombotic events in three patients in group I (three with previous cerebrovascular accidents-one additionally had two previous deep vein thromboses: during oral contraceptive use and in the postpartum period). The salicylates had been combined with prednisolone in two ofthese patients and azathioprine as well in the third. Warfarin alone prevented further complications in three patients ( Thrombotic events tended to occur at times of hypercoagulability-for example, in the postpartum period and after the administration of oral contraceptives in several patients in group I, and were precipitated by problems in anticoagulation control in the group II patients. Some 
